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syndromes (MDS) are the most frequent indications for stem
cell allografts [1]. Disease status and donor source are major
determinants of outcomes for these transplantations. Large
registry-based analyses illustrate that 3-year overall survival
and leukemia-free survival are equivalent in recipients of
matched related and matched unrelated donors in AML and
MDS [2,3]. However, one third of patients do not have a
matched donor andmay have either a mismatched unrelated
donor transplantat or depend on alternative donor stem cell
sources, such as umbilical cord blood or haploidentical
family donors for a transplantat. The experience with either
of the latter sources of stem cells is still accumulating, and
comparative studies of these with matched donors in a
disease-speciﬁc context are limited.
Haploidentical donor transplantation is an attractive op-
tion as most patients will have such a donor available.
However, severe bidirectional alloreactivity leading to non-
engraftment or severe graft-versus-host disease (GVHD)
were barriers to these types of transplantations [4]. The
Perugia protocol with T cell depletion and infusion of
megadoses of CD 34þ stem cells overcame the problems of
engraftment and GVHD, but the associated delayed immune
reconstitution resulted in infectious morbidity and mortality
[5]. Introduction of a T cellereplete reduced-intensity
conditioned haploidentical protocol by the Hopkins group,
which is based on the use of bone marrow grafts with lower
numbers of T lymphocytes followed by the infusion of high
doses of post-transplantation cyclophosphamide (Cy) be-
tween 60 to 72 hours after the infusion of stem cells to
eliminate maximally alloreactive lymphocytes but spare
CD 34þ stem cells and regulatory T lymphocytes that have
the enzyme aldehyde dehydrogenase, resulted in reliable
engraftment of neutrophils and platelets with very low rates
of acute and chronic GVHD. However, relapse rates were
relatively high [6]. Comparisons of overall survival and
disease-free survival of reduced-intensity conditioning
haploidentical bone marrow transplantations with post-
transplantation Cy with double umbilical cord blood
transplantations were similar, as the low nonrelapse mor-
tality of haploidentical was offset by the higher relapse rateDOI of original article: http://dx.doi.org/10.1016/j.bbmt.2014.08.013.
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http://dx.doi.org/10.1016/j.bbmt.2014.10.005[7]. To circumvent the higher relapse rate, myeloablative
approaches [8,9] and/or substitution of peripheral blood
stem cells have been utilized with higher rates of grade II
acute GVHD but similar rates of chronic GVHD [9-12]. These
studies have included all subtypes of hematological malig-
nancies and the relative efﬁcacy of haploidentical donor in
reducing relapse is confounded by disease variables. Notably,
comparative outcomes based on donor source for relapsed
refractory Hodgkin’s lymphoma demonstrated signiﬁcantly
lower relapse rates with improved progression-free survival
for haploidentical donors and equivalence in terms of 2-year
overall survival between matched related donors (MRD),
unrelated donors, and haploidentical transplantations [13].
In this issue, Di Stasi et al. address the same question in
AML/MDS patients by retrospectively analyzing outcomes of
nonrandomized but concurrently treated patients who un-
derwent transplantation with 10/10-matched related or un-
related donors and haploidentical donors conditioned
uniformly at their center with a ﬂudarabine/melphalan/thi-
otepaebased regimen, wherein the doses of melphalan and
thiotepa could be reduced for older patients and those with
comorbidities. Three different GHVD prophylaxis schemes,
including post-transplantation Cy, tacrolimus up to day 180,
and mycophenolate for 3 months for haploidentical donors,
tacrolimus  mini methotrexate for MRD, and additional
6 mg/kg of rabbit antithymocyte globulin for matched un-
related donors (MUD) were employed [14].
Transplantation outcomes for the entire cohort and of
those in remission at the time of transplantation showed
equivalent 3-year overall survival (matched donors, 56% and
haploidentical donors, 66%) and progression-free survival
(matched donors, 51% and haploidentical donors, 41%).The
rates of acute and chronic GVHD at day 100 and 3 years after
transplantation were also similar. Patients in complete
remission had favorable outcomes with all donor sources;
however, for patients not in complete remission, the
progression-free survival with haploidentical transplantation
appeared to beworse, although signiﬁcance was not detected.
Accompanying immune reconstitution studies suggested
that all donor types achieved normal CD3þ counts by
6 months after transplantation with a predominance of
CD3þ/CD8þ cells, which may account for the low nonrelapse
mortality in all groups. Within this, the MRD group recov-
ered CD4þ/CD8þ cells to higher levels by day 30 when
compared with haploidentical transplant recipients, and
natural killer cells were also higher in the haploidentical
group at 1 year after transplantation. Unfortunately, the
ability to derive correlations between immune reconstitu-
tion and outcomes would require larger groups of patients to
be studies.
The small cohort limits the conclusions we can draw
from this study, as exempliﬁed by the trend for MRD to
experience better progression-free survival, which may not
have been detected statistically, the possibility that acute
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plantations, which may have been signiﬁcant in a larger
cohort, and the favorable progression-free survival in the
haploidentical cohort may be attributed to larger numbers
being in remission and at low/intermediate risk at the time
of transplantation. Differences, such as bone marrow being
the stem cell source in most haploidentical recipients
whereas peripheral blood stem cells was the predominant
source in MUD/MRD groups, resulted in signiﬁcantly longer
neutrophil and platelet engraftment times but might also
have inﬂuenced the incidence of GVHD and relapse rates.
Patients undergoing haploidentical transplantations were
younger and ﬁtter group with a shorter follow up, whereas
those in the MRD/MUD group were older with comorbid-
ities. Whether older patients or those with advanced dis-
ease would have comparable results with haploidentical
transplantation cannot be determined. An adequately
powered study of all 3 donor sources undergoing identical
conditioning with post-transplantation Cy as sole prophy-
laxis and using an identical stem cell source in a single
disease matched for relapse risk to detect differences in
relapse and GVHD would be the next step. However, more
data will be needed before physicians have the conﬁdence
to randomize patients into such a trial.
Despite these limitations, this is the ﬁrst set of data
comparing haploidentical donors with 10/10 MRD in AML/
MDS, with encouraging preliminary results. The results go
someway in refuting the higher relapse rates associatedwith
haploidentical transplantation and support the authors’
assertion that haploidentical donors offer similar results to
fully matched unrelated donors in patients with AML/MDS.
For the AML/MDS patient who is in complete remission or
has low/intermediate disease, for whom no MUD is available
or the costs are unaffordable, these data would support the
use of haploidentical donors rather than a mismatched un-
related donor. Nevertheless, wemust wait for more evidence
before we equate or relegate MUD below haploidentical
donors.
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